5 Hidden Conditions Whole-body Can Help Detect

Download PDF

In general, elective whole-body imaging is designed for people without symptoms who want a proactive assessment of their health. While many diseases eventually cause symptoms, some of the most serious conditions, including pancreatic cancers, and metabolic diseases can remain silent for months or even years before becoming clinically apparent. Our Advanced Whole Body MRI™ protocol combines high-resolution MRI, low-dose Spectral CT and research-grade DEXA to provide a broader assessment than whole-body MRI alone. Together, these complementary technologies help evaluate early-stage cancer, cardiovascular disease, neurological conditions and metabolic health before symptoms develop, when treatment options may be greatest.

The conditions highlighted in this article are not exhaustive, as there are many of asymptomatic conditions which are valuable to detect early. However, it is important to note that the ability to detect these conditions depends on the imaging protocol, scanner technology, image quality and expertise of the reporting radiologist. Not all whole-body MRI providers perform the same dedicated imaging sequences or incorporate complementary imaging modalities, such as Spectral CT or DEXA, which may influence the breadth and confidence of assessment.

Why are some of the most important conditions are hard to detect early?

Many serious health conditions develop silently, without noticeable symptoms, until they have progressed to a stage where treatment options may be more limited. This is particularly true for certain cancers, including pancreatic cancer and upper gastrointestinal cancers such as oesophageal cancer, which often remain undetected in their early stages because they produce few, if any, warning signs.

When symptoms do occur, they are frequently non-specific and can mimic common, benign conditions. Fatigue, abdominal discomfort and changes in bowel habits, for example, are easily attributed to less serious causes, making early diagnosis more challenging. This is especially true in younger adults, where cancer is generally considered less likely. Importantly, the incidence of early-onset cancers (those occurring before the age of 50) is increasing, yet this younger population is not routinely included in most national screening programs. As a result, cancers in younger individuals are often diagnosed only after symptoms develop. Detecting these diseases at an earlier stage may significantly expand treatment options and improve outcomes.

Against this backdrop, there is growing interest in identifying clinically significant conditions before symptoms arise. Advances in medical imaging now make it possible to detect a range of otherwise silent abnormalities at an earlier stage, allowing timely investigation and, where appropriate, earlier intervention.

Below are five, often silent conditions, our Whole Body MRI™ protocol can help detect.

1. Pancreatic Cancer

Pancreatic cancer develops in the pancreas, a gland behind the stomach vital to digestion and blood sugar regulation. It is one of the most aggressive cancers, with an overall five-year survival rate of around 14% in Australia. When caught early, survival increases dramatically. The challenge is that the pancreas sits deep within the abdomen, inaccessible by routine physical examination, and early pancreatic cancer rarely causes pain or obvious symptoms. At present, there are no recommended screening programs in Australia for individuals considered at increase risk of developing pancreatic cancer. Due to the asymptomatic nature and high-propensity to metastasise early, most individuals are not diagnosed until the cancer has spread. However, excellent progress has been made in recent years with at 2025 study new research funded by Pankind evaluating the benefits of population screening for individuals at high risk.

How our Whole Body MRI™ scan can help detect Pancreatic Cancer

Our Whole Body MRI™ protocol includes targeted high-resolution pancreatic imaging sequences designed to optimise visualisation of the pancreas and improve the detection of pancreatic abnormalities. In addition, our true b1000 distortion-free whole-body DWIBS enhances lesion conspicuity and provides high-quality diffusion-weighted imaging throughout the body. Our low-dose Spectral CT complements MRI by providing additional anatomical information and a valuable “second look” at the upper abdomen, giving our reporting radiologists more information than just a whole body MRI alone. For patients undergoing our Executive Package, a dedicated abdominal ultrasound provides a further assessment of the pancreas and surrounding abdominal organs, offering an additional imaging perspective. Together, this multi-modal approach provides one of the most comprehensive non-invasive early detection assessments of the pancreas currently available in Australia.

This is important because when pancreatic cancer is detected while still confined to the pancreas, especially when lesions are less than 10 mm, surgical resection is more likely to be possible and may significantly improve survival rates through expanded treatment options. There are no current screening recommendations for pancreatic cancer in Australia at this time. Individuals at increased risk, such as family history or known genetic predisposition syndromes, imaging surveillance may be recommended.

2. Cancers of the Gallbladder & Bile Ducts

Cancers of the gallbladder and bile ducts (cholangiocarcinoma) are relatively rare but serious malignancies of the biliary system. Like pancreatic cancer, the gallbladder and bile ducts are notoriously difficult to detect at early stages due to its position, tucked beneath the liver. In many cases, these cancers do not produce clear symptoms in early disease, with advancing disease known to cause jaundice, fatigue, abdominal pain or unintended weight loss. The vague symptomology of these cancers, coupled with the lack of risk-factor based screening tests means that up to 80% of cases are identified at more advanced stages. While risk factors are still not fully elucidated, women and individuals with gallstones are at increased risk of developing gallbladder cancer. On the other hand, bile duct cancers are more prevalent in individuals with a history of ulcerative colitis and cirrhosis.

How our Whole Body MRI™ scan can help detect Gallbladder & Bile Duct Cancers

In general, MRI provides excellent visualisation of the liver, gallbladder and biliary tree, allowing assessment for masses, gallbladder wall thickening, bile duct narrowing, and other abnormalities that may warrant further investigation. While no imaging test can detect every cancer, our Whole Body MRI™ protocol includes targeted high-resolution sequences for of gallbladder and bile ducts, providing detailed cross-sectional imaging of these structures without IV contrast. This may help identify clinically significant abnormalities before symptoms develop, when further investigation and treatment options may be more favourable.

3. Brain Cancer

Brain cancer encompasses a broad range of tumours, including gliomas, meningiomas, and metastatic lesions from cancers elsewhere in the body. Early brain tumours are often asymptomatic or cause non-specific symptoms such as headaches, brain fog, vision disturbances and occasional memory lapses, which are easily attributed to stress, fatigue or ageing.

How our Whole Body MRI™ scan can help detect early signs of Brain Cancers

MRI is the preferred modality for most brain investigations, providing detailed views without ionising radiation. Our Whole Body MRI™ scan includes a comprehensive brain MRI with qualitative and quantitative sequences (e.g. Neuroquant & SyMRI) that can identify masses, lesions, and structural abnormalities at an early stage, when treatment options are broadest. Slow-growing tumours like meningiomas may simply be monitored; others can be surgically removed or treated surgically, or with precision radiation therapy before significant neurological damage occurs.

4. Fatty Liver Disease (NAFLD / MASLD)

Non-alcoholic fatty liver disease (NAFLD), now often referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), occurs when excess fat accumulates in the liver. The most common cause of non-alcoholic fatty liver disease include obesity and type II diabetes (e.g. metabolic syndrome), but is also associated with sugary drinks and systemic inflammation. Left untreated, it can progress to fibrosis, cirrhosis, and in some cases, liver cancer. Despite affecting an estimated 25–30% of the adult population globally, it is largely silent in its early stages, with most people experiencing no pain or discomfort until liver damage is already significant. In addition to risk for organ-specific conditions, fatty liver is also associated with sleep apnoea, kidney disease and heart disease, likely as a result of a vicious feedback cycle driving systemic inflammation.

How our Whole Body MRI™ scan can help detect early signs of Liver Disease

MRI is the most accurate non-invasive tool for quantitative assessment of liver fat content. Rather than a binary “yes” or “no”, our exclusive Whole Body MRI protocol includes a liver fat percentage (e.g. 8%) with standard risk stratification for better actionable health insights. This matters because NAFLD caught early can often be reversed or stabilised through lifestyle changes alone, minimising risk of chronic liver disease or liver cancer. In other words, early identification helps prevent irreversible progression. In conjunction with our included research-grade DEXA Body Composition and CT coronary calcium score, a broader picture of an individuals metabolic health can be obtained. It is now increasingly recognised that multi-body are interconnected – visceral fat & lean tissue (DEXA), coronary artery plaque (calcium score) and liver fat (MRI) and all are biomarkers for metabolic health status.

5. Haemochromatosis

Haemochromatosis is a condition in which the body absorbs excess iron from food, causing it to accumulate in organs such as the liver, heart, and pancreas. If left undiagnosed and untreated, iron overload can cause significant tissue damage and increase risk of heart failure, liver cirrhosis, liver cancer, loss of bone density (e.g. osteoporosis), type 3 diabetes stemming from iron-induced pancreatic damage. Importantly, early symptoms are often vague, including fatigue and joint pain which contributes to delayed diagnosis. While most cases of haemochromatosis are inherited, individuals can have haemochromatosis (or secondary iron overload) without a known family history. For individuals with a known family history, it is widely recommended to also evaluated for haemochromatosis. When identified early, haemochromatosis is highly treatable. Treatment typically involves regular phlebotomy (therapeutic blood removal) to reduce excess iron stores, while iron-chelating medications may be used in selected cases where phlebotomy is not suitable.

How our Whole Body MRI scan can help detect early signs of Haemochromatosis

Quantitative MRI is highly sensitive to iron deposition within the liver, allowing iron overload to be detected before irreversible organ damage occurs. Our exclusive Whole Body MRI™ protocol includes dedicated liver iron quantification sequences, enabling accurate, non-invasive assessment of hepatic iron stores. Because liver iron concentration closely correlates with total body iron stores, elevated liver iron may indicate abnormal iron absorption, such as hereditary haemochromatosis. Where elevated iron levels are identified, further assessment by the individual’s referring healthcare provider may be recommended, including blood tests and, where appropriate, genetic testing to confirm the diagnosis and guide management.

Conclusion

Many of the most serious health conditions develop silently, often without obvious symptoms until they have reached a more advanced stage. For asymptomatic individuals seeking a proactive assessment of their health, advanced imaging can provide valuable insights that may not otherwise be available through routine health checks alone. While no imaging test can detect every disease or guarantee the early detection of every cancer, our multi-modal approach is designed to maximise the opportunity to identify clinically significant abnormalities before symptoms develop. Earlier detection may allow earlier investigation, expand treatment options and, in many cases, improve long-term health outcomes.

For more information on conditions our exclusive Whole Body MRI protocol can detect, visit Our Reports page. If you would like to learn more, Contact Us or our partner clinic MBR Health.

Author: Dr A. Forbes (PhD)